Effectiveness of the Eczema Action Plan (EAP) in improving the Eczema Area and Severity Index (EASI) scores among pediatric patients with atopic dermatitis: A pragmatic randomized controlled trial
51573 Dupilumab Treatment for up to 5 Years Improves Eczema Area and Severity Index Score Across all Anatomical Regions in Adults With Moderate-to-Severe Atopic Dermatitis
